Autor(es):
Araujo,Alexandra P. Q. C. ; Carvalho,Alzira A. S. de ; Cavalcanti,Eduardo B. U. ; Saute,Jonas Alex M. ; Carvalho,Elmano ; França Junior,Marcondes C. ; Martinez,Alberto R. M. ; Navarro,Monica de M. M. ; Nucci,Anamarli ; Resende,Maria Bernadete D. de ; Gonçalves,Marcus Vinicius M. ; Gurgel-Giannetti,Juliana ; Scola,Rosana H. ; Sobreira,Cláudia F. da R. ; Reed,Umbertina C. ; Zanoteli,Edmar
Data: 2017
Origem: Oasisbr
Assunto(s): muscular dystrophy, Duchenne; practice guideline; consensus; diagnosis; genetic testing; drug therapy; glucocorticoids; utrophin
Descrição
ABSTRACT Significant advances in the understanding and management of Duchenne muscular dystrophy (DMD) took place since international guidelines were published in 2010. Our objective was to provide an evidence-based national consensus statement for multidisciplinary care of DMD in Brazil. A combination of the Delphi technique with a systematic review of studies from 2010 to 2016 was employed to classify evidence levels and grade of recommendations. Our recommendations were divided in two parts. We present Part 1 here, where we describe the guideline methodology and overall disease concepts, and also provide recommendations on diagnosis, steroid therapy and new drug treatment perspectives for DMD. The main recommendations: 1) genetic testing in diagnostic suspicious cases should be the first line for diagnostic confirmation; 2) patients diagnosed with DMD should have steroids prescribed; 3) lack of published results for phase 3 clinical trials hinders, for now, the recommendation to use exon skipping or read-through agents.
